Jerome Wittamer

Our in vitro model allows for the first time the identification and differentiation of respiratory sensitizers and respiratory irritants under air-liquid interphase realistic exposure conditions.

The worlds first space focused pre-clinical contract research organization. Our mission is to extend and improve life on Earth and in Space. We use microgravity as a new dimension for biology to accelerate drug discovery and unlock therapies that are very hard or even impossible to develop on Earth. We’re building the world’s first standardized space-based high-throughput testing platform, allowing pharma and biotech partners to run automated experiments in orbit, at scale. By combining microgravity with advanced lab automation and bioinformatics, we create more physiologically relevant models, observe faster disease development, and reach enhanced 3D biology compared to standard in-vitro systems. The goal is simple: make space a routine, essential part of the biomedical R&D pipeline so we can bring better and faster treatments to patients.

HelloBetter is a European leader in the field of digital therapeutics (DTx) for mental health and a global pioneer in digital mental health research. Founded in 2015, HelloBetter has the strongest evidence base globally, with a total of 33 randomized controlled trials published in peer-reviewed journals. In Germany, six of their therapy programmes are part of the standard of care and as such available to 70+ million people for free as prescription digital therapeutics or DiGA. In 2022, HelloBetter entered the US market with its HelloGina brand which offers a sexual wellness program for people with vaginismus. In 2023, HelloBetter received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its digital therapeutic HelloBetter Panic.

Deliver data-driven investment decisions, faster, with greater transparency and at scale with our next-generation machine-learning technology. Accelex allows investors and servicers in alternative assets to quickly and easily acquire, extract and analyze investment data. Using artificial intelligence and machine learning, Accelex allows clients to automate the accessing, extracting, organizing and analyzing of data from alternative investment portfolios. This offers clients a more complete picture of investments from the overall portfolio all the way down to the underlying assets. Accelex is headquartered in London with offices in Paris, Luxembourg, New York and Toronto. For more information please visit: www.accelextech.com

Finally, a password manager built for organizations that take their security and privacy seriously. Passbolt is trusted by 15 000 of them worldwide, including F500 companies, the defense industry, universities, startups and many others.

Next Gate Tech is a fintech company specializing in the automation of data management and analytics for the financial sector. The company leverages the latest technologies, to provide clients with all their data from multiple unharmonized sources, as one consistent, consolidated, and independent source enabling them to streamline their day-to-day processes. Next Gate Tech SaaS solution leverages the harmonized datasets to provide its clients with meaningful signals based on smart analytics and insights from their assets which can be leveraged for different use cases such as NAV Oversight, Risk analytics, Investment Management supervision, Compliance or ESG.

Pliops accelerates and amplifies the performance and scalability of global GenAI infrastructure, driving unparalleled efficiency and innovation. Pliops was founded in 2017 by storage industry veterans from Samsung, M-Systems, and XtremIO. Pliops is pioneering a new category of product that enables cloud and enterprise data centers to access data up to 50 times faster with one-tenth of the computational load and power consumption. Its technology consolidates multiple inefficient layers into one ultra-fast device based on a groundbreaking approach. Pliops’ solution addresses the scalability challenges posed by the cloud data explosion and the increasing data demands of AI and ML applications.

LuxCloud is a leader in Cloud Service Brokerage enablement, offering a one-stop shop for cloud business applications, allowing Sales Partners to quickly launch and profitably deliver their cloud services under their own brand, demanded by Small and Medium sized Businesses. LuxCloud provides customizable and scalable white label solutions to Value-Added Resellers, IT distributors, Hosters and Telco’s. The range of applications is constantly evolving, reflecting the needs of the market, and includes Web and application hosting, messaging and collaboration, business processes and infrastructure packages. Part of the DCL Group, LuxCloud was founded in 2010 and is based in Luxembourg. Supported by an international in-house expert team, your business will experience a smooth transition into the cloud. START YOUR CLOUD BUSINESS TODAY www.luxcloud.com

Our in vitro model allows for the first time the identification and differentiation of respiratory sensitizers and respiratory irritants under air-liquid interphase realistic exposure conditions.

The worlds first space focused pre-clinical contract research organization. Our mission is to extend and improve life on Earth and in Space. We use microgravity as a new dimension for biology to accelerate drug discovery and unlock therapies that are very hard or even impossible to develop on Earth. We’re building the world’s first standardized space-based high-throughput testing platform, allowing pharma and biotech partners to run automated experiments in orbit, at scale. By combining microgravity with advanced lab automation and bioinformatics, we create more physiologically relevant models, observe faster disease development, and reach enhanced 3D biology compared to standard in-vitro systems. The goal is simple: make space a routine, essential part of the biomedical R&D pipeline so we can bring better and faster treatments to patients.

HelloBetter is a European leader in the field of digital therapeutics (DTx) for mental health and a global pioneer in digital mental health research. Founded in 2015, HelloBetter has the strongest evidence base globally, with a total of 33 randomized controlled trials published in peer-reviewed journals. In Germany, six of their therapy programmes are part of the standard of care and as such available to 70+ million people for free as prescription digital therapeutics or DiGA. In 2022, HelloBetter entered the US market with its HelloGina brand which offers a sexual wellness program for people with vaginismus. In 2023, HelloBetter received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its digital therapeutic HelloBetter Panic.

Deliver data-driven investment decisions, faster, with greater transparency and at scale with our next-generation machine-learning technology. Accelex allows investors and servicers in alternative assets to quickly and easily acquire, extract and analyze investment data. Using artificial intelligence and machine learning, Accelex allows clients to automate the accessing, extracting, organizing and analyzing of data from alternative investment portfolios. This offers clients a more complete picture of investments from the overall portfolio all the way down to the underlying assets. Accelex is headquartered in London with offices in Paris, Luxembourg, New York and Toronto. For more information please visit: www.accelextech.com

Finally, a password manager built for organizations that take their security and privacy seriously. Passbolt is trusted by 15 000 of them worldwide, including F500 companies, the defense industry, universities, startups and many others.